
Acer Therapeutics (ACER) Stock Forecast & Price Target
Acer Therapeutics (ACER) Analyst Ratings
Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%
Acer Therapeutics (ACER) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Acer Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Acer Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Acer Therapeutics (ACER) Analyst Forecast & Price Prediction
Get the latest Acer Therapeutics (ACER) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Acer Therapeutics (ACER)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Acer Therapeutics (ACER) Forecast
Analysts have given Acer Therapeutics (ACER) a Buy based on their latest research and market trends.
According to 6 analysts, Acer Therapeutics (ACER) has a Buy consensus rating as of Aug 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.